COYA Coya Therapeutics | $4.74
| 6/12/2026 | | Reiterated Rating | $14.00 | Buy | 00.00% | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 6/12/2026 |
PURR Hyperliquid Strategies | $8.70
| 6/12/2026 | | Reiterated Rating | $9.75 | Buy | 00.00% | View details for Chardan Capital rating of Hyperliquid Strategies (NASDAQ:PURR) on 6/12/2026 |
ZOOZ ZOOZ Power | $5.35
| 6/12/2026 | | Lower Price Target | $40.00 ➝ $10.00 | Buy | 00.00% | View details for Chardan Capital rating of ZOOZ Power (NASDAQ:ZOOZ) on 6/12/2026 |
CAMP CAMP4 Therapeutics | $4.19
| 6/10/2026 | | Set Price Target | $6.50 | Buy | 00.00% | View details for Chardan Capital rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 6/10/2026 |
CAMP CAMP4 Therapeutics | $4.19
| 6/10/2026 | | Initiated Coverage | $6.50 | Buy | 00.00% | View details for Chardan Capital rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 6/10/2026 |
PHMMF Pharma Mar | $79.49
| 6/9/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Pharma Mar (OTCMKTS:PHMMF) on 6/9/2026 |
VFS VinFast Auto | $3.15
| 6/9/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 6/9/2026 |
CLSK Cleanspark | $16.48
| 6/8/2026 | | Boost Price Target | $16.00 ➝ $19.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 6/8/2026 |
HYPD Hyperion DeFi | $2.72
| 6/8/2026 | | Lower Price Target | $8.25 ➝ $7.30 | Buy | 00.00% | View details for Chardan Capital rating of Hyperion DeFi (NASDAQ:HYPD) on 6/8/2026 |
KEEL Keel Infrastructure | $5.59
| 6/8/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 6/8/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
PVLA Palvella Therapeutics | $108.81
| 5/21/2026 | | Reiterated Rating | $240.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 5/21/2026 |
PURR Hyperliquid Strategies | $8.70
| 5/20/2026 | | Boost Price Target | $8.45 ➝ $9.75 | Buy | 00.00% | View details for Chardan Capital rating of Hyperliquid Strategies (NASDAQ:PURR) on 5/20/2026 |
ALMS Alumis | $24.15
| 5/19/2026 | | Boost Price Target | $38.00 ➝ $40.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 5/19/2026 |
IMRX Immuneering | $4.19
| 5/19/2026 | | Reiterated Rating | $20.00 | Buy | 00.00% | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 5/19/2026 |
IMTX Immatics | $9.38
| 5/19/2026 | | Reiterated Rating | $25.00 | Buy | 00.00% | View details for Chardan Capital rating of Immatics (NASDAQ:IMTX) on 5/19/2026 |
SNTI Senti Biosciences | $0.96
| 5/15/2026 | | Boost Price Target | $11.00 ➝ $12.00 | Buy | 00.00% | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 5/15/2026 |
KEEL Keel Infrastructure | $5.59
| 5/11/2026 | | Reiterated Rating | $4.50 | Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 5/11/2026 |
KOD Kodiak Sciences | $34.06
| 5/11/2026 | | Upgrade | $14.00 ➝ $61.00 | Neutral ➝ Buy | 00.00% | View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 5/11/2026 |
LXEO Lexeo Therapeutics | $4.37
| 5/11/2026 | | Reiterated Rating | $17.00 | Buy | 00.00% | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 5/11/2026 |
RCKT Rocket Pharmaceuticals | $2.75
| 5/11/2026 | | Reiterated Rating | $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/11/2026 |
KDK Kodiak AI | $6.14
| 5/8/2026 | | Lower Price Target | $22.00 ➝ $15.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 5/8/2026 |
IOVA Iovance Biotherapeutics | $4.08
| 5/7/2026 | | Lower Price Target | $16.00 ➝ $14.00 | Buy | 00.00% | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/7/2026 |
CLYM Climb Bio | $11.44
| 5/5/2026 | | Initiated Coverage | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Climb Bio (NASDAQ:CLYM) on 5/5/2026 |
EDIT Editas Medicine | $2.50
| 5/5/2026 | | Boost Price Target | $3.50 ➝ $4.00 | Buy | 00.00% | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 5/5/2026 |
GLXY Galaxy Digital | $33.36
| 5/4/2026 | | Reiterated Rating | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of Galaxy Digital (NASDAQ:GLXY) on 5/4/2026 |
KEEL Keel Infrastructure | $5.59
| 5/4/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 5/4/2026 |
RIOT Riot Platforms | $26.61
| 5/4/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Chardan Capital rating of Riot Platforms (NASDAQ:RIOT) on 5/4/2026 |
QURE uniQure | $27.57
| 4/30/2026 | | Boost Price Target | $31.00 ➝ $37.00 | Buy | 00.00% | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 4/30/2026 |
RIOT Riot Platforms | $26.61
| 4/27/2026 | | Initiated Coverage | $27.50 | Buy | 00.00% | View details for Chardan Capital rating of Riot Platforms (NASDAQ:RIOT) on 4/27/2026 |
GLXY Galaxy Digital | $33.36
| 4/27/2026 | | Initiated Coverage | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of Galaxy Digital (NASDAQ:GLXY) on 4/27/2026 |
KEEL Keel Infrastructure | $5.59
| 4/27/2026 | | Initiated Coverage | $4.50 | Buy | 00.00% | View details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 4/27/2026 |
NTLA Intellia Therapeutics | $12.11
| 4/27/2026 | | Boost Price Target | $27.00 ➝ $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026 |
VFS VinFast Auto | $3.15
| 4/23/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/23/2026 |
ANRO Alto Neuroscience | $21.57 +0.4% | 4/22/2026 | | Reiterated Rating | $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 4/22/2026 |
PASG Passage Bio | $5.81
| 4/21/2026 | | Set Price Target | $21.00 ➝ $7.00 | Buy ➝ Neutral | 00.00% | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 4/21/2026 |
PASG Passage Bio | $5.81
| 4/21/2026 | | Downgrade | $21.00 ➝ $7.00 | Buy ➝ Hold | 00.00% | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 4/21/2026 |
IOVA Iovance Biotherapeutics | $4.08
| 4/10/2026 | | Reiterated Rating | $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 4/10/2026 |
IBIO iBio | $1.69
| 4/9/2026 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 4/9/2026 |
PRQR ProQR Therapeutics | $1.44
| 4/9/2026 | | Reiterated Rating | $4.00 | Buy | 00.00% | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 4/9/2026 |
CLSK Cleanspark | $16.48
| 4/8/2026 | | Reiterated Rating | $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 4/8/2026 |
Read now. Do not delete. You’ve been warned. (Ad) Three Nobel Prize Winners expose this once-in-a-generation wealth shift:
“Don’t Say I Didn’t Warn You”
Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. Don’t be left behind. Click here now. |
ANRO Alto Neuroscience | $21.57 +0.4% | 4/2/2026 | | Reiterated Rating | $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 4/2/2026 |
PVLA Palvella Therapeutics | $108.81
| 3/31/2026 | | Boost Price Target | $210.00 ➝ $240.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 3/31/2026 |
ALMS Alumis | $24.15
| 3/30/2026 | | Reiterated Rating | $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 3/30/2026 |
MNPR Monopar Therapeutics | $59.77
| 3/30/2026 | | Reiterated Rating | $100.00 | Buy | 00.00% | View details for Chardan Capital rating of Monopar Therapeutics (NASDAQ:MNPR) on 3/30/2026 |
SNTI Senti Biosciences | $0.96
| 3/30/2026 | | Lower Price Target | $13.00 ➝ $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 3/30/2026 |
ZOOZ ZOOZ Power | $5.35
| 3/30/2026 | | Reiterated Rating | $40.00 | Buy | 00.00% | View details for Chardan Capital rating of ZOOZ Power (NASDAQ:ZOOZ) on 3/30/2026 |
CGTX Cognition Therapeutics | $1.21
| 3/27/2026 | | Reiterated Rating | $4.00 | Buy | 00.00% | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 3/27/2026 |
MGTX MeiraGTx | $9.59
| 3/27/2026 | | Reiterated Rating | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 3/27/2026 |
RCKT Rocket Pharmaceuticals | $2.75
| 3/27/2026 | | Reiterated Rating | $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 3/27/2026 |
ALNY Alnylam Pharmaceuticals | $282.85
| 3/25/2026 | | Reiterated Rating | $425.00 | Buy | 00.00% | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 3/25/2026 |
KDK Kodiak AI | $6.14
| 3/25/2026 | | Reiterated Rating | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 3/25/2026 |
OCGN Ocugen | $1.21
| 3/25/2026 | | Reiterated Rating | $7.00 | Buy | 00.00% | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/25/2026 |
ZURA Zura Bio | $3.70
| 3/23/2026 | | Boost Price Target | $10.00 ➝ $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 3/23/2026 |
ALMS Alumis | $24.15
| 3/20/2026 | | Boost Price Target | $37.00 ➝ $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 3/20/2026 |
ANNX Annexon | $4.71
| 3/20/2026 | | Reiterated Rating | $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Annexon (NASDAQ:ANNX) on 3/20/2026 |
SLDB Solid Biosciences | $7.14
| 3/20/2026 | | Reiterated Rating | $15.00 | Buy | 00.00% | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/20/2026 |
FDMT 4D Molecular Therapeutics | $8.83
| 3/19/2026 | | Reiterated Rating | $26.00 | Buy | 00.00% | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 3/19/2026 |
TSHA Taysha Gene Therapies | $5.71
| 3/19/2026 | | Reiterated Rating | $12.00 | Buy | 00.00% | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 3/19/2026 |
CRVO CervoMed | $2.45
| 3/18/2026 | | Boost Price Target | $15.00 ➝ $21.00 | Buy | 00.00% | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/18/2026 |
IBIO iBio | $1.69
| 3/18/2026 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 3/18/2026 |
STOK Stoke Therapeutics | $29.82
| 3/18/2026 | | Reiterated Rating | $35.00 | Buy | 00.00% | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 3/18/2026 |
ANRO Alto Neuroscience | $21.57 +0.4% | 3/17/2026 | | Reiterated Rating | $30.00 | Buy | 00.00% | View details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 3/17/2026 |
ULYX Urgent.ly | $5.50
| 3/17/2026 | | Downgrade | $15.00 ➝ $5.50 | Buy ➝ Hold | 00.00% | View details for Chardan Capital rating of Urgent.ly (OTCMKTS:ULYX) on 3/17/2026 |
VFS VinFast Auto | $3.15
| 3/17/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/17/2026 |
COYA Coya Therapeutics | $4.74
| 3/16/2026 | | Reiterated Rating | $14.00 | Buy | 00.00% | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/16/2026 |
PVLA Palvella Therapeutics | $108.81
| 3/16/2026 | | Reiterated Rating | $210.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 3/16/2026 |
IRD Opus Genetics | $4.04
| 3/12/2026 | | Boost Price Target | $9.00 ➝ $11.00 | Buy | 00.00% | View details for Chardan Capital rating of Opus Genetics (NASDAQ:IRD) on 3/12/2026 |
OBIO Orchestra BioMed | $4.10
| 3/12/2026 | | Reiterated Rating | $20.00 | Buy | 00.00% | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/12/2026 |
SLDB Solid Biosciences | $7.14
| 3/12/2026 | | Reiterated Rating | $15.00 | Buy | 00.00% | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/12/2026 |
TNYA Tenaya Therapeutics | $0.71
| 3/12/2026 | | Reiterated Rating | $8.00 | Buy | 00.00% | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2026 |
KDK Kodiak AI | $6.14
| 3/11/2026 | | Reiterated Rating | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 3/11/2026 |
SABS SAB Biotherapeutics | $3.33
| 3/11/2026 | | Boost Price Target | $12.00 ➝ $14.00 | Buy | 00.00% | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 3/11/2026 |
DYN Dyne Therapeutics | $18.19
| 3/9/2026 | | Reiterated Rating | $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/9/2026 |
EDIT Editas Medicine | $2.50
| 3/9/2026 | | Reiterated Rating | $3.50 | Buy | 00.00% | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 3/9/2026 |
QURE uniQure | $27.57
| 3/9/2026 | | Boost Price Target | $16.00 ➝ $31.00 | Buy | 00.00% | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 3/9/2026 |
CRVO CervoMed | $2.45
| 3/5/2026 | | Reiterated Rating | $15.00 | Buy | 00.00% | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/5/2026 |
OCGN Ocugen | $1.21
| 3/5/2026 | | Reiterated Rating | $7.00 | Buy | 00.00% | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/5/2026 |
EYPT Eyepoint Pharmaceuticals | $13.03
| 3/4/2026 | | Boost Price Target | $27.00 ➝ $29.00 | Buy | 00.00% | View details for Chardan Capital rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 3/4/2026 |
QURE uniQure | $27.57
| 3/3/2026 | | Lower Price Target | $53.00 ➝ $16.00 | Buy | 00.00% | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 3/3/2026 |
VFS VinFast Auto | $3.15
| 3/3/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/3/2026 |
DYN Dyne Therapeutics | $18.19
| 3/2/2026 | | Reiterated Rating | $38.00 | Buy | 00.00% | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/2/2026 |
NTLA Intellia Therapeutics | $12.11
| 2/27/2026 | | Reiterated Rating | $26.00 | Buy | 00.00% | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/27/2026 |
IOVA Iovance Biotherapeutics | $4.08
| 2/25/2026 | | Lower Price Target | $17.00 ➝ $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 2/25/2026 |
PVLA Palvella Therapeutics | $108.81
| 2/24/2026 | | Boost Price Target | $174.00 ➝ $210.00 | Buy | 00.00% | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 2/24/2026 |
KDK Kodiak AI | $6.14
| 2/19/2026 | | Reiterated Rating | $22.00 | Buy | 00.00% | View details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 2/19/2026 |
KRYS Krystal Biotech | $317.97
| 2/18/2026 | | Boost Price Target | $220.00 ➝ $323.00 | Buy | 00.00% | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 2/18/2026 |
OCUL Ocular Therapeutix | $8.94
| 2/18/2026 | | Reiterated Rating | $21.00 | Buy | 00.00% | View details for Chardan Capital rating of Ocular Therapeutix (NASDAQ:OCUL) on 2/18/2026 |
OTLK Oncobiologics | $1.22
| 2/18/2026 | | Reiterated Rating | | Neutral | 00.00% | View details for Chardan Capital rating of Oncobiologics (NASDAQ:OTLK) on 2/18/2026 |
CRSP CRISPR Therapeutics | $49.80
| 2/14/2026 | | Boost Price Target | $74.00 ➝ $76.00 | Buy | 00.00% | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2026 |
ALNY Alnylam Pharmaceuticals | $282.85
| 2/13/2026 | | Lower Price Target | $475.00 ➝ $425.00 | Buy | 00.00% | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/13/2026 |
Before you buy SpaceX shares, consider this alternative approach (Ad) SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history.
But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered. Discover the overlooked SpaceX IPO strategy before the June listing |
IBIO iBio | $1.69
| 2/12/2026 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 2/12/2026 |
PURR Hyperliquid Strategies | $8.70
| 2/12/2026 | | Boost Price Target | $8.15 ➝ $8.45 | Buy | 00.00% | View details for Chardan Capital rating of Hyperliquid Strategies (NASDAQ:PURR) on 2/12/2026 |
PASG Passage Bio | $5.81
| 2/10/2026 | | Initiated Coverage | $21.00 | Buy | 00.00% | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 2/10/2026 |
RGNX REGENXBIO | $6.66
| 2/10/2026 | | Lower Price Target | $52.00 ➝ $50.00 | Buy | 00.00% | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 2/10/2026 |
VFS VinFast Auto | $3.15
| 2/10/2026 | | Reiterated Rating | $5.50 | Buy | 00.00% | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 2/10/2026 |
CLSK Cleanspark | $16.48
| 2/6/2026 | | Lower Price Target | $30.00 ➝ $16.00 | Buy | 00.00% | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 2/6/2026 |
KRRO Korro Bio | $11.61
| 1/29/2026 | | Upgrade | $15.00 | Neutral ➝ Buy | 00.00% | View details for Chardan Capital rating of Korro Bio (NASDAQ:KRRO) on 1/29/2026 |
MNPR Monopar Therapeutics | $59.77
| 1/29/2026 | | Reiterated Rating | $100.00 | Buy | 00.00% | View details for Chardan Capital rating of Monopar Therapeutics (NASDAQ:MNPR) on 1/29/2026 |
RGNX REGENXBIO | $6.66
| 1/29/2026 | | Reiterated Rating | $52.00 | Buy | 00.00% | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 1/29/2026 |
ALMS Alumis | $24.15
| 1/21/2026 | | Initiated Coverage | $37.00 | Buy | 00.00% | View details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 1/21/2026 |